Location History:
- Lennik, BE (2013)
- Sint-Kwintens-Lennik, BE (2015)
Company Filing History:
2 out of 94 
1 out of 12 
1 out of 5 Years Active: 2013-2015
Title: Innovations in Pancreatic Beta Cell Research by Inventor Daisy Flamez
Introduction
Daisy Flamez, an innovative inventor based in Sint-Kwintens-Lennik, Belgium, has made significant contributions to the field of pancreatic beta cell research. With two patents to her name, she focuses on advancing the understanding of pancreatic beta cells, which play a crucial role in glucose metabolism and diabetes management.
Latest Patents
Daisy's latest patents reflect her commitment to enhancing diagnostic and therapeutic strategies related to pancreatic beta cells. Her first patent introduces a synthetic peptide molecule that specifically binds to the FXYD2-gamma isoform of pancreatic beta cells. This 25-amino-acid synthetic peptide holds promise for advancing diagnostic techniques and potentially therapeutic applications.
The second patent focuses on identifying plasma membrane biomarkers preferentially expressed in pancreatic beta cells. This invention utilizes a Systems Biology approach, analyzing Massively Parallel Signal Sequencing datasets from human islets and Affymetrix microarray datasets with purified rat primary beta and non-beta cells. The identified biomarker possesses five specific features, making it a unique candidate for imaging and targeting strategies in various medical scenarios, including Type 1 and Type 2 diabetes, pancreatic cancers, obesity, islet transplantation, and beta cell regeneration.
Career Highlights
Throughout her career, Daisy Flamez has collaborated with notable institutions, including the Université Libre de Bruxelles and the Université de Mons. Her work in these prestigious organizations has contributed to her research specialization and the successful development of her innovative patents.
Collaborations
In her journey, Daisy has had the opportunity to work alongside esteemed colleagues such as Decio L. Eizirik and Marie-Claire Beckers. These collaborations have enriched her research experience and allowed for the exchange of innovative ideas in pancreatic beta cell studies.
Conclusion
Daisy Flamez's pioneering work in identifying biomarkers and developing novel peptides underscores her impact on pancreatic beta cell research. With two significant patents, she continues to pave the way for advancements in diabetes diagnostics and treatment, offering hope for improved health outcomes in patients worldwide. Her contributions reflect the essence of innovation in scientific research, ultimately aiming to enhance the understanding and treatment of diseases affecting pancreatic beta cells.